2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
CCO’s expert faculty review and share their expert perspectives on key findings in nonmalignant hematologic disorders presented at the 2019 ASH annual meeting.
Hanny Al-Samkari, MD
Sujit Sheth, MD

Nonmalignant Hematology

Slidesets Updated Results From a Randomized Phase III Trial of Avatrombopag in Patients With Chronic ITP
Slidesets BELIEVE Subanalysis: Evaluation of Responders With Transfusion-Dependent β-Thalassemia to Luspatercept
Slidesets Interim Results From the Phase III Northstar-3 (HGB-212) Study of Betibeglogene Autotemcel in Patients With Severe Transfusion-Dependent β-Thalassemia
Slidesets Phase I/II Evaluation of Novel BTKi PRN1008 in R/R Primary or Secondary Immune Thrombocytopenia
Slidesets Phase I Trial of Sutimlimab to Inhibit Classical Complement Pathway in Patients With Multi-Refractory Chronic Immune Thrombocytopenia
Slidesets CARDINAL: Phase III Study of Sutimlimab in Patients With Cold Agglutinin Disease and a Recent History of Transfusion
Slidesets Pilot Feasibility Study of BCL11A as Gene Therapy Target in Sickle Cell Disease

In this commentary, Hanny Al-Samkari, MD, and Sujit Sheth, MD, provide insights on key studies in nonmalignant hematologic disorders presented at ASH 2019.

Hanny Al-Samkari, MD Sujit Sheth, MD Released: February 18, 2020
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo
Contact Info

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue